华氏巨球蛋白血症患者的治疗目标应该是什么？完全缓解应该是治疗的目标。
What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy.
作者信息
Treon Steven P, Castillo Jorge J
机构信息
Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA; and Department of Medicine, Harvard Medical School, Boston MA.
出版信息
Blood Adv. 2017 Nov 28;1(25):2486-2490. doi: 10.1182/bloodadvances.2017005637.
Abstract
.
摘要
.
相似文献
1
What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy.华氏巨球蛋白血症患者的治疗目标应该是什么？完全缓解应该是治疗的目标。
Blood Adv. 2017 Nov 28;1(25):2486-2490. doi: 10.1182/bloodadvances.2017005637.
2
Disease control should be the goal of therapy for WM patients.疾病控制应是华氏巨球蛋白血症患者治疗的目标。
Blood Adv. 2017 Nov 28;1(25):2483-2485. doi: 10.1182/bloodadvances.2017005645.
3
Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm.雷帕霉素哺乳动物靶点抑制剂治疗期间的药物相关性肺炎：以华氏巨球蛋白血症为例基于影像学模式的方法
Oncologist. 2015 Sep;20(9):1077-83. doi: 10.1634/theoncologist.2015-0033. Epub 2015 Jul 23.
4
Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应作为骨髓瘤治疗的终点吗？
Blood Adv. 2017 Mar 14;1(8):522-525. doi: 10.1182/bloodadvances.2017000109.
5
Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.预防血管性血友病（VWD）相关产后出血的抗纤溶治疗：适应证与局限性
Blood Adv. 2017 Apr 25;1(11):699-702. doi: 10.1182/bloodadvances.2017005082.
6
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).前瞻性、多中心临床试验：依维莫司作为华氏巨球蛋白血症（WMCTG09-214）的一线治疗药物。
Clin Cancer Res. 2017 May 15;23(10):2400-2404. doi: 10.1158/1078-0432.CCR-16-1918. Epub 2016 Nov 11.
7
Platelets as immune-sensing cells.血小板作为免疫感知细胞。
Blood Adv. 2016 Nov 22;1(1):10-14. doi: 10.1182/bloodadvances.2016000067. eCollection 2016 Nov 29.
8
Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.缺氧促进华氏巨球蛋白血症中新骨髓微环境中的播散和定植。
Mol Cancer Res. 2015 Feb;13(2):263-72. doi: 10.1158/1541-7786.MCR-14-0150. Epub 2014 Sep 17.
9
Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia.多发性骨髓瘤和华氏巨球蛋白血症中的基因组学和蛋白质组学。
Curr Opin Hematol. 2007 Jul;14(4):369-74. doi: 10.1097/MOH.0b013e3281ddb2b8.
10
ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.异基因干细胞移植中的抗胸腺细胞球蛋白：2017年的治疗标准？反对观点。
Blood Adv. 2017 Mar 28;1(9):573-576. doi: 10.1182/bloodadvances.2016001552.
引用本文的文献
1
Polyclonal Immunotactoid Glomerulopathy Associated with Monoclonal Gammopathy of IgM Type and Underlying Plasmacellular Disease: Successful Treatment with Rituximab Alone.与IgM型单克隆丙种球蛋白病及潜在浆细胞疾病相关的多克隆免疫触须样肾小球病：单用利妥昔单抗治疗成功
Case Rep Nephrol Dial. 2022 Apr 25;12(1):63-72. doi: 10.1159/000524131. eCollection 2022 Jan-Apr.
2
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.伊布替尼单药治疗有症状、既往治疗的华氏巨球蛋白血症患者的长期随访。
J Clin Oncol. 2021 Feb 20;39(6):565-575. doi: 10.1200/JCO.20.00555. Epub 2020 Sep 15.
本文引用的文献
1
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.伊布替尼在华氏巨球蛋白血症中的停药：病因、结果和 IgM 反弹。
Am J Hematol. 2018 Aug;93(4):511-517. doi: 10.1002/ajh.25023. Epub 2018 Jan 25.
2
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.与华氏巨球蛋白血症中依鲁替尼耐药相关的获得性突变。
Blood. 2017 May 4;129(18):2519-2525. doi: 10.1182/blood-2017-01-761726. Epub 2017 Feb 24.
3
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.维奈托克在复发或难治性非霍奇金淋巴瘤患者中的I期首次人体研究。
J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.
4
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.伊布替尼治疗利妥昔单抗难治性华氏巨球蛋白血症患者（iNNOVATE）：一项国际多中心 3 期临床试验的开放性亚研究。
Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.
5
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.初诊 WM 患者中的 BDR：至少随访 6 年后的 2 期研究的最终分析。
Blood. 2017 Jan 26;129(4):456-459. doi: 10.1182/blood-2016-09-742411. Epub 2016 Nov 21.
6
Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.瓦尔登斯特伦巨球蛋白血症第八次国际研讨会的治疗建议。
Blood. 2016 Sep 8;128(10):1321-8. doi: 10.1182/blood-2016-04-711234. Epub 2016 Jul 18.
7
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.转录组测序揭示了一种与华氏巨球蛋白血症基因组变异相对应的特征。
Blood. 2016 Aug 11;128(6):827-38. doi: 10.1182/blood-2016-03-708263. Epub 2016 Jun 14.
8
Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.华氏巨球蛋白血症中与依鲁替尼相关的心房颤动。
Am J Hematol. 2016 Jun;91(6):E312-3. doi: 10.1002/ajh.24366. Epub 2016 Apr 28.
9
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.华氏巨球蛋白血症中CXCR4 WHIM样突变的克隆结构
Br J Haematol. 2016 Mar;172(5):735-44. doi: 10.1111/bjh.13897. Epub 2015 Dec 13.
10
Rituximab intolerance in patients with Waldenström macroglobulinaemia.华氏巨球蛋白血症患者对利妥昔单抗不耐受
Br J Haematol. 2016 Aug;174(4):645-8. doi: 10.1111/bjh.13794. Epub 2015 Nov 2.
Zotero 插件